Free Trial

Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.22

Amicus Therapeutics logo with Medical background

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.22.

Several analysts have issued reports on FOLD shares. The Goldman Sachs Group lowered their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th.

Check Out Our Latest Research Report on FOLD

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in Amicus Therapeutics during the 4th quarter worth about $132,000. AlphaQuest LLC boosted its position in Amicus Therapeutics by 635.1% during the fourth quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company's stock worth $101,000 after purchasing an additional 9,272 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in Amicus Therapeutics by 35.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock worth $2,850,000 after purchasing an additional 79,602 shares during the period. Swiss National Bank boosted its position in Amicus Therapeutics by 0.7% during the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after purchasing an additional 3,200 shares during the period. Finally, Cibc World Markets Corp acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $259,000.

Amicus Therapeutics Trading Down 0.9%

NASDAQ FOLD traded down $0.06 during mid-day trading on Wednesday, hitting $6.37. The company's stock had a trading volume of 561,970 shares, compared to its average volume of 3,788,130. Amicus Therapeutics has a 52-week low of $5.51 and a 52-week high of $12.65. The stock's fifty day simple moving average is $6.09 and its two-hundred day simple moving average is $7.84. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47. The firm has a market capitalization of $1.96 billion, a P/E ratio of -70.71 and a beta of 0.51.

About Amicus Therapeutics

(Get Free Report

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Featured Articles

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Should You Invest $1,000 in Amicus Therapeutics Right Now?

Before you consider Amicus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.

While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines